Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

• Status: Not yet recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BAMF Health
• Collaborator: Telix International Pty Ltd
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Male ≥ 18 years of age

3. Patients meeting clinical need for Illuccix PET scan:

1. Patients with suspected metastasis who are candidates for initial definitive therapy

2. Patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level

4. Patient is physically able to lay flat for the PET-CT procedure

Exclusion Criteria:

1. Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.